Medpace (MEDP) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $707.3 million, up 17.2% year-over-year (YoY).

Year-to-Date Revenue: $1.41 billion, a 21.7% increase YoY.

EBITDA: $153.4 million, a 17.6% increase from $130.5 million in Q2 2025.

EBITDA Margin: 21.7%, slightly up from 21.6% YoY; year-to-date margin at 21.4%, flat YoY.

Net Income: $121.4 million, up 34.5% YoY; year-to-date net income at $245.2 million, a 19.7% increase.

Net Income per Diluted Share: $4.25 for the quarter, compared to $3.10 in Q2 2025.

Net New Business Awards: $795.7 million, a 28.2% increase YoY, with a net book-to-bill ratio of 1.13x.

Ending Backlog: Approximately $3 billion, up 4.9% YoY; projected revenue conversion from backlog in the next 12 months is $1.96 billion.

Cash Flow from Operations: $162 million; cash at quarter-end was $502.7 million.

Share Repurchases: 706,000 shares repurchased for $294.7 million; $527 million remaining under the repurchase program.

2Strategic Updates and Business Highlights

The business environment in Q2 was strong, with well-managed cancellations and record net bookings.

RFPs (Requests for Proposals) increased both sequentially and YoY, indicating a robust pipeline of opportunities.

Oncology trials have seen a resurgence, contributing over half of the overall bookings, while the metabolic segment has seen a decline.

Initiatives to improve win rates have been implemented, contributing to strong performance in Q1 and Q2.

The company is positioning itself for growth in 2027, with a focus on diversifying its client base to mitigate customer concentration risks.

3Forward Guidance and Outlook

2026 Total Revenue Guidance: Expected in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14% over 2025.

2026 EBITDA Guidance: Projected between $618 million and $642 million, reflecting growth of 10.8% to 15.1% YoY.

Net Income Guidance: Expected between $494 million and $514 million, with earnings per diluted share projected at $17.25 to $17.95.

4Bad News, Challenges, or Points of Concern

Cancellations, while improved, remain unpredictable and can significantly impact future bookings.

The concentration of revenue from the top five and ten customers is a concern, as they represent 31% and 40% of revenue, respectively.

The decline in metabolic program awards could signal a shift in business dynamics, potentially affecting future revenue streams.

The company is cautious about predicting future cancellation rates, which could introduce volatility in revenue recognition.

5Notable Q&A Insights

The CEO confirmed that the growth in net awards was significantly driven by large programs in the metabolic sector, but oncology is regaining strength.

There is uncertainty regarding the timing of when increased funding in biotech will translate into awards and backlog.

The company has tightened its policies on backlog recognition, which has contributed to a higher backlog burn rate.

The competitive landscape remains stable, with no significant changes in pricing or competition noted.

The company expects a ramp-up in gross bookings in the second half of 2026, driven by a strong pipeline and reduced cancellations. Overall, Medpace demonstrated solid financial performance in Q2 2026, with a strong outlook for the remainder of the year, despite some concerns regarding customer concentration and the unpredictability of cancellations.